Table 7.
Evaluation of pharmacokinetic parameters of control and optimized methotrexate patches.
| Formulations | Tmax(h) | Cmax(ng/mL) | t1/2 | K (h−1) | AUC0-t (ng/mL.h) | MRT (h) |
|---|---|---|---|---|---|---|
| Control (F5) | 10 | 167.80 ± 3.41 | 15.91 ± 2.11 | 0.040 ± 0.02 | 2765.15 ± 132.1 | 11.65 ± 0.52 |
| F5 E-Oil 5% | 8 | 176.13 ± 4.51 | 17.15 ± 2.51 | 0.031 ± 0.01 | 2884.51 ± 131.5 | 23.81 ± 0.61 |
| F5 NMP 5% | 8 | 171.61 ± 2.15 | 18.93 ± 2.13 | 0.032 ± 0.02 | 2693.14 ± 147.3 | 22.21 ± 0.61 |
| F5 OA 10% | 8 | 178.07 ± 2.75 | 21.49 ± 1.16 | 0.027 ± 0.05 | 2949.27 ± 192.7 | 25.63 ± 0.51 |
| Two-way ANNOVA ‘P’ | ns | <0.05 (s) | <0.05 (s) | <0.01 (HS) | <0.01 (HS) | |
Note: Cm MRT: mean residence time. AUC0-t: area under the plasma concentration-time plot from 0 h to time. K(h−1): elimination rate constant. t1/2: elimination half-life. Cmax: peak plasma drug concentration. Tmax: time at which Cmax was observed.